Loading the security page…
A security analysis is not yet prepared for this market.
Based on the last 12 months of reports, through 30 June 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
Fate Therapeutics, Inc. (FATE) is a company in the Health care sector; its shares trade on Nasdaq.
The price of Fate Therapeutics, Inc. (FATE) on November 11, 2026 is 1.66 $, −6.50 % on the day. Over 52 weeks the stock traded between 0.9500 $ and 3.23 $; the price now sits 31 % of the way up that range. Over the past year the price changed by +81.31 %. Market capitalization is 205.38 million $, rank 70 among 134 stocks of the same industry with a known capitalization.
Fate Therapeutics, Inc. trades on Nasdaq under the ticker FATE. The company belongs to the Health care sector. The trading history on this page starts on 22 August 2016.
Over the past 52 weeks FATE has traded between 0.9500 $ and 3.23 $. As of 11 November 2026 the price stood 43.42% of the way from the 52-week low to the high.
Over one year FATE shares rose 81.31%; over six months they fell 11.01%. Volatility over 90 days is 63.70%. Dividends are not included: this is price change only, as of 11 November 2026.
The company reported a loss over the last four quarters, so a price-to-earnings ratio is not calculated. Price to sales is 31.6, above the sector median of 3.7. Price to book is 1.3, below the sector median of 2.3. Calculated from reports for the period ending 30 June 2026.
Fate Therapeutics, Inc. reported revenue of 6M $ and a net loss of 126M $ over the last four quarters. Net margin is −1,941.09%. Revenue changed by −23.36% year over year. Earnings per share are −$1.05. Market capitalisation is 205M $.
FATE has a return on equity of −82.12%, below the sector median of −40.58%. Return on assets is −48.44%, below the sector median of −30.08%. Operating margin is −2,058.08%, below the sector median of −20.96%.